1403387-46-1

Basic information

• Product Name: 1-bromo-3-(1-methylcyclopropyl)-5-(trifluoromethyl)benzene
• Synonyms: 1-bromo-3-(1-methylcyclopropyl)-5-(trifluoromethyl)benzene
• CAS NO: 1403387-46-1
• Molecular Weight: 279.1
• Mol File: 1403387-46-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-bromo-3-(1-methylcyclopropyl)-5-(trifluoromethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-3-(1-methylcyclopropyl)-5-(trifluoromethyl)benzene(1403387-46-1)
• EPA Substance Registry System: 1-bromo-3-(1-methylcyclopropyl)-5-(trifluoromethyl)benzene(1403387-46-1)

Safety Data

• Hazardous Substances Data: 1403387-46-1(Hazardous Substances Data)

Upstream product

• 401-84-3 1,3-dibromo-5-(trifluoromethyl)benzene 
• 75-11-6 diiodomethane 
• 1403387-45-0 1-bromo-3-(prop-1-en-2-yl)-5-(trifluoromethyl)benzene 

Downstream Products

• 1403387-44-9 4,4,5,5-tetramethyl-2-(3-(1-methylcyclopropyl)-5-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane 

Relevant articles and documents

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.